瑞普生物(300119.SZ):獲得豬流行性腹瀉病毒mRNA疫苗(RPS1903)臨牀試驗批件
格隆匯7月25日丨瑞普生物(300119.SZ)公佈,近日,瑞普生物股份有限公司收到了農業農村部頒發的豬流行性腹瀉病毒mRNA疫苗(RPS1903)臨牀試驗批件(批件號:2025061)。
此次獲得的臨牀批件,是國內首個經濟動物用mRNA疫苗臨牀批件。mRNA疫苗通過精準編碼豬流行性腹瀉病毒的關鍵抗原序列,進入機體後直接引導細胞合成抗原蛋白,從而激發強效免疫反應。與傳統疫苗相比,mRNA疫苗在研發效率、免疫效果及生物安全風險防控等方面,具備明顯優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.